Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01636622 · ClinicalTrials.gov registry record · Phase 1
Study of Vemurafenib, Carboplatin, and Paclitaxel
A Phase 1 study of Advanced Cancers, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01636622: Completed Phase 1 study of Advanced Cancers, sponsored by M.D. Anderson Cancer Center.
NCT01636622 is a Phase 1 study of Advanced Cancers that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants, below the 68-participant average among 10 other Advanced Cancers trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01636622, a Phase 1 study of Advanced Cancers, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with carboplatin and paclitaxel patients with advanced cancer. The safety of the study drug combination will also be studied. Vemurafenib is designed to block a protein (called mutated BRAF) that is only found in moles (spots) of the skin and certain types of cancer cells. This drug may slow the growth of or kill these cells. Carboplatin is designed to slow the growth of cancer cells by stopping them from making new DNA (the genetic material of cells). Paclitaxel is designed to slow the growth of cancer cells by stopping them from dividing into new cells.
Primary Outcome
Maximum tolerated dose (MTD) defined as highest dose studied in which the incidence of the dose limiting toxicity (DLT) is \< 33%. If at any time more than or equal to one third of participants at a dose level experience DLT, that dose is considered to be above the MTD.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Vemurafenib
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-07-09 |
| Est. Completion | 2020-04-21 |
| Phase | Phase 1 |
What the finished NCT01636622 record still lists
NCT01636622 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 68-participant average among 10 other Advanced Cancers trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Advanced Cancers appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT01636622 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01636622 about?
NCT01636622 is a clinical study titled "Study of Vemurafenib, Carboplatin, and Paclitaxel". The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with carboplatin and paclitaxel patients with advanced cancer. The safety of the study drug combination will also be studied. Vemurafenib is designed to block a protein (ca...
What is the current status of trial NCT01636622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2012-07-09. Estimated completion is 2020-04-21.
What conditions does trial NCT01636622 study?
This clinical trial studies the following conditions: Advanced Cancers.
What interventions are being tested in trial NCT01636622?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Vemurafenib (DRUG).
Who is sponsoring clinical trial NCT01636622?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01636622 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01636622's enrollment target sits among peer trials
21 9th of 10 higher than 2 of 10 other Advanced Cancers trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
The Effects of Ginseng on Cancer-Related Fatigue
ACTIVE NOT RECRUITING · Phase 1
-
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
COMPLETED · Phase 1
-
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
COMPLETED · Phase 1
-
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
COMPLETED · Phase 1
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI